EGFR and lung cancer: CXCL8 is associated with resistance to multiple chemotherapeutic approaches including platinum-based drugs in ovarian cancer [202], epidermal growth factor receptor (EGFR) inhibitors in lung cancer [203], cisplatin and doxorubicin in hepatocellular carcinoma [204], and gemcitabine in pancreatic cancer [205].